Cresemba is an azole antifungal that inhibits the synthesis of ergosterol, a key component of the fungal cell membrane. Depletion of ergosterol within the fungal cell membrane weakens the membrane structure and function.
Cresemba received Orphan Drug and Qualified Infectious Disease Product (QIDP) designations and is approved for the treatment of invasive aspergillosis and invasive mucormycosis in patients aged ≥18. Its priority review and subsequent approval was based on a clinical trial involving 516 patients randomized to either Cresemba or voriconazole for the treatment of invasive aspergillosis, as well as a single-arm clinical trial involving 37 patients treated with Cresemba for mucormycosis. Results from both studies showed that Cresemba was safe and effective in treating the fungal infections.
Cresemba is available as oral 186mg capsules in 7-count blister packs, and as single-dose 372mg vials for injection.
For more information call (877) 828-7942 or visit Astellas.com.